Gemtuzumab ozogamicin

Known as: Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody, gemtuzumab-ozogamicin, hP67.6-Calicheamicin 
A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin. In this conjugate, the antibody… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults, with an incidence of over 6500 cases per… (More)
  • table 1
Is this relevant?
Highly Cited
2013
Highly Cited
2013
This randomized phase 3 clinical trial evaluated the potential benefit of the addition of gemtuzumab ozogamicin (GO) to standard… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE There has been little survival improvement in older patients with acute myeloid leukemia (AML) in the last two decades… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND The results of the addition of gemtuzumab ozogamicin, an anti-CD33 antibody conjugate, to the standard treatment for… (More)
Is this relevant?
Review
2011
Review
2011
Antibody-drug conjugates (ADC) are an attractive approach for the treatment of acute myeloid leukemia and non-Hodgkin lymphomas… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE We examined the outcome of patients with newly diagnosed acute promyelocytic leukemia (APL) treated with all-trans… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
The anti-CD33 antibody calicheamicinconjugate gemtuzumab ozogamicin (GO) was used to treat 16 patients with acute promyelocytic… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
CD33 is expressed by acute myeloid leukemia (AML) cells in >80% of patients but not by normal hematopoietic stem cells… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
We analyzed the safety and efficacy of Mylotarg (gemtuzumab ozogamicin, an antibody-targeted chemotherapy consisting of a… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Highly Cited
2001
Highly Cited
2001
PURPOSE Three open-label, multicenter trials were conducted to evaluate the efficacy and safety of single-agent Mylotarg… (More)
Is this relevant?